Why Is Ionis Pharmaceuticals Stock at a 52-Week Low on Monday?

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) stock is trading at a 52-week low after the company lowered Tryngolza (olezarsen) 2026 product sales guidance.

• Ionis Pharmaceuticals shares are approaching critical lows. What’s behind IONS weakness?

Tryngolza Guidance Reduction

The cholesterol-lowering drug generated U.S. net product sales of $9 million in the third quarter.

The company expects 2026 Tryngolza sales of approximately $50 million compared to prior sales of $100 million-$110 million, citing that the severe hypertriglyceridemia (sHTG) launch is progressing more gradually than expected, reflecting early dynamics of establishing a new treatment paradigm.

Q3 Financial Results Top Wall Street Expectations

The company reported a third-quarter adjusted loss of 40 cents, beating the consensus loss of $1.21. Sales jumped 55% year over year to $243 million, beating the Wall Street consensus of $182.12 million.

Ionis affirmed its 2026 sales guidance of $875 million-$900 million versus the analysts’ estimate of $916.396 million, with plans to achieve positive cash flow by 2029, contingent on Tringolza’s uptake and pipeline successes.

Leadership Defends Multibillion-Dollar Long-Term Peak Sales Potential

In an earnings call, the company said it is confident in Tringolza’s multibillion-dollar peak sales potential, with strategic initiatives focused on broadening prescriber base, increasing prescribing depth, and improving payer access.

CEO Brett Monia told investors that as the first and only treatment approved to reduce triglycerides and the risk of acute pancreatitis in people living with SHTG, Tryngolza requires health care professionals to adopt a new approach to patient care, which takes time in these early days.

“While initial sales progress has been more gradual than anticipated, we are encouraged by the underlying launch fundamentals. Importantly, we have identified clear opportunities to improve performance, and we remain confident in TRYNGOLZA’s long-term growth potential,” Monia said in a press release on Monday.

Monia commented that the company remains confident in Tryngolza’s potential to achieve more than $3 billion in peak annual sales.

Dawnzera Sales Keep Pace with Full-Year 2026 Projections

Dawnzera (donidalorsen), the first and only RNA-targeted prophylactic therapy for hereditary angioedema (HAE) in patients 12 years of age and older, generated sales of $37 million.

The company is on track to achieve full-year 2026 Dawnzera sales guidance of $110-120 million.

IONS Price Action: Ionis Pharmaceuticals shares were down 24.25% at $29.867 at the time of publication on Monday. The stock is trading at a new 52-week low, according to Benzinga Pro data.

Photo: Shutterstock